Introduction {#sec1}
============

Rhabdomyosarcoma (RMS) is a rare and highly malignant mesenchymal tumor [@bib1], [@bib2]. It is a common childhood cancer comprising more than 50% of all pediatric soft tissue sarcomas (STSs). In contrast, RMS is uncommon in adults and comprises \<1% of all adult malignancies. RMS accounts for 3% of all STS [@bib3], [@bib4]. Histologically, RMSs are classified into three major subgroups: embryonal RMS, pleomorphic RMS, and alveolar RMS. Pleomorphic RMS and alveolar RMS have poor prognosis compared with embryonal RMS [@bib5], [@bib6].

Most RMSs are diagnosed in patients younger than 10 years old and these patients have better outcomes compared with older patients [@bib7], [@bib8], [@bib9]. Adult patients had poor prognosis, and overall survival (OS) at 5 years was \<40% [@bib5]. In contrast, 5-year OS for younger patients was \>60% [@bib10]. However, for adult patients with metastatic disease, the 5 year survival was \<5% [@bib11], [@bib12].

Adult RMS is a highly malignant tumor with a significant incidence of metastatic recurrence [@bib12]. Novel more effective treatment is needed for adult RMS. RMS in the adult population has a low incidence; therefore, the study of RMS in this group is challenging. Clinically-relevant mouse models of RMS could permit evaluation of tailor-made therapy based on the patient-derived tumor. We have developed the patient-derived orthotopic xenograft (PDOX) nude mouse model for all major cancers [@bib13]. Recently, we have reported a comparative study of PDOX nude mouse model and subcutaneous xenografted model of adult pleomorphic RMS [@bib14]. The behavior of the PDOX mouse model was more similar to the patient tumor in growth and local aggressiveness.

Caffeine (CAF) (1,3,7-trimethylxanthine) is a natural stimulatory compound and shown to be effective against tumors by inducing apoptosis [@bib15], [@bib16], [@bib17]. CAF can also overcome chemotherapy- or radiation-induced delays in cell cycle progression [@bib18], [@bib19], thereby enhancing their efficacy [@bib20].

Valproic acid (VPA), a short-chain fatty acid, is widely used to treat epilepsy and has been reported to be a potent histone deacetylase (HDAC) inhibitor. HDAC inhibitors can induce apoptosis, cell differentiation, autophagy, and are anti-angiogenic [@bib21]. VPA has been used for treatment of myelodysplastic syndrome [@bib22], melanoma [@bib23], and solid tumors [@bib24]. We have reported the synergistic efficacy of the combination of CAF and VPA for sarcomas [@bib25].

The tumor-targeting *Salmonella typhimurium* A1-R (*S. typhimurium* A1-R), developed by our laboratory [@bib26], is auxotrophic for Leu--Arg, which prevents it from mounting a continuous infection in normal tissues. *S. typhimurium* A1-R was shown to be effective against primary and metastatic tumors in PDOX models of major cancers [@bib27], [@bib28], [@bib29], [@bib30].

In the present study, we evaluated the efficacy of *S. typhimurium* A1-R alone and in combination with CAF and VPA on a PDOX model of adult pleomorphic RMS.

Materials and Methods {#sec2}
=====================

Animal Care {#sec2.1}
-----------

Athymic nu/nu nude mice (AntiCancer Inc., San Diego, CA), 4- to 6-week old, were used in this study [@bib14]. All animal studies were conducted with an AntiCancer Inc., Institutional Animal Care and Use Committee protocol specifically approved for this study and in accordance with the principles and procedures outlined in the National Institutes of Health Guide for the Care and Use of Animals under Assurance Number A3873-1 [@bib14]. Animal suffering was avoided by using anesthesia and analgesics for all surgical experiments. Detailed protocols of handling animals, feeding, anesthesia, injection, and humane endpoint criteria were described in previous publication [@bib14].

Patient-Derived Tumor {#sec2.2}
---------------------

A 68-year-old male diagnosed with pleomorphic RMS in a large primary right-high-thigh tumor underwent surgical resection at the Department of Surgery, University of California, Los Angeles (UCLA). He did not receive any chemotherapy or radiotherapy before surgery. Written informed consent was obtained from the patient as part of a UCLA Institutional Review Board (IRB \#10-001857)-approved protocol [@bib14]. Briefly, the subcutaneous tumor was harvested and divided into 3-4mm^3^ fragments and one fragment was inserted in the left biceps femoris muscle using the technique of surgical orthotopic implantation (SOI) [@bib14].

Surgical Orthotopic Implantation for Establishment of PDOX Model {#sec2.3}
----------------------------------------------------------------

Detailed protocols for obtaining a fresh sample of the tumor of the patient, its transportation to the laboratory at AntiCancer Inc., tumor fragmentation, subcutaneous implantation in nude mice, establishing a PDOX model, and wound closure were previously described [@bib14].

Primary Culture of Patient-Derived Tumor {#sec2.4}
----------------------------------------

After the RMS was grown and established in nude mice, the grown tumors were harvested and were cut into small fragments (1 mm or less). Then fragments were placed in RPMI1640 supplemented with 10% fetal bovine serum (FBS) into a 25 cm^2^ sterile flask. The cell culture was rinsed the next day with phosphate-buffered saline (PBS) twice to remove nonadherent cells and excess tissue in the flask. The medium was changed every 3--4 days thereafter.

Growth Inhibition Assay {#sec2.5}
-----------------------

Cellular viability was assessed using the WST-8 dye reduction assay. Cells were seeded in 96-well flat-bottomed microplates (100 μL/well) at a 5 × 10^4^ cells/mL density, incubated at 37 °C for 24 h, and exposed to various concentrations of tested compounds for 72 h. For each concentration, at least 8 wells were used. After incubation with the test compounds, 10 μl WST-8 solution was added to each well. The microplates were further incubated for 3 h at 37 °C, and absorption was measured using a microprocessor-controlled microplate reader (SunriseTM; TECAN, San Joes, CA, USA) at 450 nm. Cell-survival fractions were calculated as the percentage of untreated control cells. IC~50~ values were derived from concentration--response curves.

Calculation of Combination Index {#sec2.6}
--------------------------------

The specific interaction between CAF and VPA on the RMS cell lines was evaluated by the combination index (CI) assay using CalcuSyn software from ComboSyn Inc. (New Jersey, USA), with the method of Chou and Martin [@bib31]. In this analysis, synergy was defined as a CI \< 1.0, antagonism as a CI \> 1.0, and additivity as CI values not significantly different from 1.0.

Preparation and Administration of *S. typhimurium* A1-R {#sec2.7}
-------------------------------------------------------

GFP-expressing *S. typhimurium* A1-R bacteria (AntiCancer Inc.,) were grown overnight in LB medium (Fisher Sci., Hanover Park, IL, USA) and then diluted 1:10 in LB medium. Bacteria were harvested at late-log phase, washed with PBS, and then diluted in PBS. *S. typhimurium* A1-R was injected intravenously. A total of 5 × 10^7^ CFU *S. typhimurium* A1-R in 100 μl PBS was administered to each mouse [@bib30], [@bib32], [@bib33].

Confocal Microscopy {#sec2.8}
-------------------

The FV1000 confocal microscope (Olympus, Tokyo, Japan) was used for high-resolution imaging. Fluorescence images were obtained using the 20×/0.50 UPlan FLN and 40×/1.3 oil Olympus UPLAN FLN objectives [@bib34].

Distribution of *S. typhimurium* A1-R in Adult Pleomorphic RMS PDOX Mouse {#sec2.9}
-------------------------------------------------------------------------

Six PDOX mouse models were treated with *S. typhimurium* A1-R-GFP (5 × 10^7^ CFU/100 μl, i.v., once) when tumor volume reached 500 mm^3^. The PDOX tumors and tibialis anterior muscle of the affected limb were resected on day 1 and day 3 from three mice. The distribution of *S. typhimurium* A1-R was accessed by confocal imaging with the FV1000 [@bib35]. Random three fields were accessed for each specimen.

Treatment Study Design in the PDOX Model of Adult Pleomorphic RMS {#sec2.10}
-----------------------------------------------------------------

PDOX mouse models were randomized into four groups of eight mice each when tumor volume reached 100 mm^3^: G1, control without treatment; G2, treated with cyclophosphamide (CPA) (140 mg/kg, intraperitoneal (i.p.) injection, weekly, for 3 weeks); G3, treated with CAF (100 mg/kg, i.p., daily, for 3 weeks) combined with VPA (500 mg/kg, i.p., daily for 3 weeks); G4, *S. typhimurium* A1-R (5 × 10^7^ CFU/100 μl, i.v., weekly, for 3 weeks); and G5, *S. typhimurium* A1-R combined with CAF and VPA (5 × 10^7^ CFU/100 μl, i.v., weekly, for 3 weeks, 100 mg/kg, i.p., daily for 3 weeks and 500 mg/kg, i.p., daily for 3 weeks, respectively). Tumor size and body weight was measured with calipers and a digital balance twice a week. Tumor length, width, and mouse body weight was measured twice per week. Tumor volume was calculated by the following formula: Tumor volume (mm^3^) = length (mm) × width (mm) × width (mm) × 1/2. Data were presented as mean ± SD.

Results {#sec3}
=======

*In Vitro* Combination Effect of CAF and VPA on Adult Pleomorphic RMS Cell in Culture {#sec3.1}
-------------------------------------------------------------------------------------

The cytotoxic activity of CAF and VPA was determined in an adult pleomorphic RMS cell line which was established from a patient-derived xenograft. Cells were incubated for 72 h with each compound. Cell survival was evaluated as described in the Materials and Methods. To evaluate the potential combined effect of CAF and VPA, the CI values were determined using the WST-8 assay. Addition of 0.5 mM CAF in 1 mM VPA enhanced anti-proliferation activity against adult pleomorphic RMS cells ([Figure 1](#fig1){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}). In addition, the CI values were significantly \<1 which revealed synergy at all explored concentrations in the adult pleomorphic RMS cell line ([Table 2](#tbl2){ref-type="table"}). Thus, we found a synergistic effect for the combination of CAF and VPA in the adult pleomorphic RMS cell line.Figure 1Effect of caffeine (CAF) and valproic acid (VPA) on adult pleomorphic RMS cell in culture. Growth inhibitory activity of CAF and VPA or their combination against an adult pleomorphic rhabdomyosarcoma cell line AC-RMS01.Figure 1Table 1IC50 Value of Valproic Acid Against Rhabdomyosarcoma Cells with and Without Adding 0.5 mM and 1 mM of Caffeine. AC-RMS01 Cells were incubated with each drug for 72 h and then assessed via the WST-8 assayTable 1VPA IC~50~ (μg/mL)+CAF 0.5 mM+CAF 1 mMAC-RMS01353.6 ± 32.9204.9 ± 20.2\*\*156.1 ± 23.7\*\*[^1]Table 2CI Value of Combination of Caffeine and Valproic AcidTable 2Drug concentrationCIDrug concentrationCICAFVPACAFVPA0.550.00.696411.050.00.803470.5100.00.751051.0100.00.836140.5250.00.840271.0250.00.940980.5500.00.841291.0500.00.899640.51000.00.89631.01000.00.96722[^2]

Tumor Targeting of *S. typhimurium* A1-R-GFP in an Adult Pleomorphic RMS PDOX Mouse Model {#sec3.2}
-----------------------------------------------------------------------------------------

Tumor targeting of *S. typhimurium* A1-R-GFP was demonstrated by confocal imaging with the FV1000 on day 1 and day 3 after intravenous injection of *S. typhimurium* A1-R-GFP ([Figure 2](#fig2){ref-type="fig"}). The mean fluorescence intensity of *S. typhimurium* A1-R-GFP of the PDOX tumor on day 1 and day 3 was 4.63 × 10^5^ and 6.57 × 10^6^, respectively (*P* = 0.017; [Figure 3](#fig3){ref-type="fig"}A). The fluorescence area of *S. typhimurium* A1-R-GFP of the PDOX tumor on day 1 and day 3 was 23.2 ± 6.4 μm^2^ and 89.1 ± 27.0 μm^2^, respectively (*P* = 0.045; [Figure 3](#fig3){ref-type="fig"}B).Figure 2Fluorescence imaging of *Salmonella typhimurium* A1-R-GFP. Fluorescence confocal imaging of *S. typhimurium* A1-R-GFP targeting the adult pleomorphic RMS PDOX. Bars: 12.5 μm.Figure 2Figure 3Fluorescence of *Salmonella typhimurium* A1-R-GFP targeting the adult pleomorphic RMS PDOX. (A) Fluorescence intensity of *S. typhimurium* A1-R-GFP on the adult pleomorphic RMS PDOX. (B) Fluorescence area of *S. typhimurium* A1-R-GFP on the adult pleomorphic RMS PDOX.Figure 3

*S. typhimurium* A1-R-GFP was not detected by the FV1000 both on day 1 and day 3 in the tibialis anterior muscle of affected limb ([Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}).

Effect of CPA, VPA, and CAF Combination with *S. typhimurium* A1-R on the Adult Pleomorphic RMS PDOX Mouse Model {#sec3.3}
----------------------------------------------------------------------------------------------------------------

On day 21 after initiation of treatment, mean tumor volume of each group was measured: control (G1): 585.6 ± 193.1 mm^3^; CPA (G2): 297.3 ± 48.6 mm^3^; VPA + CAF (G3): 232.9 ± 43.9 mm^3^; *S. typhimurium* A1-R (G4): 193.0 ± 46.4 mm^3^; *S. typhimurium* A1-R combined with VPA and CAF (G5): 88.3 ± 29.1 mm^3^ ([Figure 4](#fig4){ref-type="fig"}A and B). All treatments significantly inhibited tumor growth compared with the untreated control ([Figure 4](#fig4){ref-type="fig"}): (CPA: *P* = 0.0019; VPA combined with CAF: *P* = 0.0005; *S. typhimurium* A1-R: *P* = 0.0002; *S. typhimurium* A1-R combined with VPA and CAF: *P* \< 0.0001). *S. typhimurium* A1-R combined with VPA and CAF was significantly more effective than either CPA (*P* \< 0.0001), VPA combined with CAF (*P* \< 0.0001) or *S. typhimurium* A1-R alone (*P* \< 0.0001) ([Figure 4](#fig4){ref-type="fig"}B). *S. typhimurium* A1-R combined with VPA and CAF significantly regressed the tumor volume compared with day 0 (*P* = 0.03) ([Figure 4](#fig4){ref-type="fig"}B). There were no animal deaths in any group. The body weight of treated mice was not significantly different in any group.Figure 4(A) Treatment scheme. (B) Efficacy of cyclophosphamide (CPA), VPA combined with CAF, *Salmonella typhimurium* A1-R (A1-R) and A1-R combined with VPA and CAF on the adult pleomorphic rhabdomyosarcoma PDOX. \**P* \< 0.0001. Tumor volume was measured at the indicated time points after the onset of treatment. n = 8 mice/group.Figure 4

Histology {#sec3.4}
---------

High-power photomicrographs of the original patient tumor demonstrated solid sheets of cancer cells characterized by pleomorphic, hyperchromatic, enlarged nuclei with coarse chromatin and moderate amounts of lightly eosinophilic cytoplasm. Numerous mitotic figures, including atypical forms, are present ([Figure 5](#fig5){ref-type="fig"}A). A high-power view of the orthotopically implanted tumor demonstrated identical features including pleomorphic, hyperchromatic, enlarged nuclei with coarse chromatin and moderate amounts of lightly eosinophilic cytoplasm. Numerous mitotic figures, including atypical forms, are also present. The histology of the -untreated PDOX tumor closely matched the patient\'s tumor with the cells of both looking very similar ([Figure 5](#fig5){ref-type="fig"}B), demonstrating the fidelity of the PDOX tumor. Tumors treated with CPA comprised viable cells without apparent necrosis or inflammatory changes ([Figure 5](#fig5){ref-type="fig"}C). Tumors treated with CAF combined with VPA and treated with *S. typhimurium* A1-R show changes in cancer cell shapes and reduced cellularity ([Figure 5](#fig5){ref-type="fig"}D and E). Tumors treated with CAF combined with VPA and *S. typhimurium* A1-R show apparent tumor necrosis with tissue fibrosis ([Figure 5](#fig5){ref-type="fig"}F).Figure 5Tumor histology. H & E-stained section of the original patient tumor (A); untreated PDOX tumor (B); PDOX tumor treated with CPA (C); PDOX tumor treated with VPA combined with CAF (D); PDOX tumor treated with *Salmonella typhimurium* A1-R (E); and PDOX tumor treated with CAF combined with VPA and *S. typhimurium* A1-R (F). Scale bars: 80 μm.Figure 5

Discussion {#sec4}
==========

Bone sarcomas and STS are rare and heterogeneous group of cancers distinguished into more than 100 subtypes. Doxorubicin (DOX) and cisplatinum (CDDP) are still the standard and most effective therapeutics after four decades. For advanced sarcoma, patient treatment outcomes are unsatisfactory. Clinical trials evaluating the efficacy of novel systemic treatment including targeted and immune therapy in sarcoma have been limited because of the rarity and heterogeneity of these tumors.

The response rates of STSs to chemotherapy are relatively low (20--30%). Patients who respond to systemic therapy have significantly improved outcomes [@bib35]. PDX models have provided a way for more clinically-relevant individualized mouse models of sarcoma that recapitulate local tumor behavior and mimic tumor-specific drug sensitivity. However, subcutaneous models of cancer rarely metastasize and few PDX models replicate advanced disease states [@bib13].

PDOX models of sarcoma behave quite similar to patient sarcoma with regard to recurrence after surgery [@bib14], metastasis [@bib36], and invasively grow to surrounding tissues [@bib14]. These properties present the opportunity to test multiple therapeutic agents [@bib36], [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49], including targeted therapy [@bib38] and experimental therapy such as novel platinum agents [@bib43], and tumor-targeting *S. typhimurium* A1-R [@bib46], [@bib47], [@bib48] in a preclinical model, without the patient suffering from the potential toxicity and morbidity of ineffective drugs. In the present study, *S. typhimurium* A1-R combined with CAF and VPA regressed an adult pleomorphic RMS PDOX model.

Cell cycle arrest is crucial for cell differentiation. p21 is a cyclin-dependent kinase (CDK) inhibitor gene which is important regulator of the cell cycle. VPA induces suppression of cyclin--CDK complexes through acetylation of histone H3 level in p21 promoter and blockage of phosphorylation of retinoblastoma protein, resulting in G~0~/G~1~ arrest [@bib50], [@bib51], [@bib52]. *S. typhimurium* A1-R decoys quiescent cancer cells in tumors from G~0~/G~1~ to S/G~2~/M phase with subsequent apoptosis [@bib53]. CAF may induce the apoptosis of cancer cells arrested *by S. typhimurium* A1-R by inducing mitotic catastrophe [@bib20]. The histological data ([Figure 5](#fig5){ref-type="fig"}) show reduced cellularity in all treatment groups with the greatest reduction in the group treatment with *S. typhimurium* A1-R combined with CAF and VPA. These data are consistent with the tumor regression in this group and indicate extensive apoptosis. Future experiments will use specific apoptosis markers and will test the individual and combined effect of these interventions on apoptosis.

Conclusions {#sec5}
===========

Our results suggest that *S. typhimurium* A1-R combined with VPA and CAF could regress an adult pleomorphic RMS in a PDOX model and therefore has important future clinical potential for patients.

Conflict of Interest {#sec6}
====================

K.I., K.K., Q.H., S.L., Y.T., T.K., K.M., M.M., T.H., and R.M.H. are or were unsalaried associates of AntiCancer Inc. MZ is the employee of AntiCancer Inc. AntiCancer Inc. uses PDOX models for contract research. The authors declare that they have no other competing interests.

This paper is dedicated to the memory of AR Moosa, MD; Sun Lee, MD; Professor Li Jiaxi, and Masaki Kitajima, MD.

[^1]: \*\* *p*\<0.001.

[^2]: The CI values were calculated in each combination ratio. The CI values of \<1, 1, or \>1 indicate synergism, additively, and antagonism, respectively.
